Compare American Homes 4 Rent Class A (AMH) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Homes 4 Rent Class A vs Inovio Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $33.27 (market cap $11.97B), while Inovio Pharmaceuticals Inc trades at $1.2 (market cap $97.91M). The key difference: American Homes 4 Rent Class A is far larger — about 122.3× Inovio Pharmaceuticals Inc's market cap, and American Homes 4 Rent Class A pays a 3.97% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMH | INO | |
|---|---|---|
Market Cap | $11.97B | $97.91M |
Sector | Real Estate | Health |
52-Week High | $36.74 | $2.87 |
52-Week Low | $27.38 | $1.05 |
Enterprise Value | $17.05B | $68.92M |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.
Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.
INO trades at $1.18, down 0.84% with bearish technical signals. The company shows minimal revenue of $65K against massive losses, with a net margin of -130,000% and negative cash flow. Recent news highlights an active FDA review for INO-3107 with an October 2026 decision date, while multiple law firms investigate potential fiduciary breaches by directors.
The investment case hinges on the binary FDA approval of INO-3107. While analyst consensus is 53% buy-rated, fundamental metrics are deeply negative. Key risks include clinical trial outcomes, cash burn, and legal scrutiny. Upside depends entirely on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
